Human umbilical cord blood-derived stromal cells prevent graft-versus-host disease in mice following haplo-identical stem cell transplantation

Cytotherapy

Volumn 13, Issue 1, 2011, Pages 83-91

  Hao, Lei ^a   Gao, Lei ^a   Chen, Xing Hua ^a   Zou, Zhong Min ^a   Zhang, Xi ^a   Kong, Pei Yan ^a   Zhang, Cheng ^a   Peng, Xian Gui ^a   Sun, Ai Hua ^a   Wang, Qing Yu ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Graft versus host disease; Haplo identical stem cell transplantation; Regulatory T cell; Stromal cell; Umbilical cord blood

Indexed keywords

ALLOPHYCOCYANIN; B7 ANTIGEN; BETA1 INTEGRIN; CD31 ANTIGEN; CD34 ANTIGEN; CD40 LIGAND; CD45 ANTIGEN; CD68 ANTIGEN; CD86 ANTIGEN; FLUORESCEIN ISOTHIOCYANATE DEXTRAN; GLYCOPROTEIN P 15095; HERMES ANTIGEN; INTERCELLULAR ADHESION MOLECULE 3; PHYCOERYTHRIN; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BONE MARROW CELL; CD4+ T LYMPHOCYTE; CELL CULTURE; CONTROLLED STUDY; FLOW CYTOMETRY; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HAPLOIDY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN UMBILICAL CORD BLOOD DERIVED STROMAL CELL; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IRRADIATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SPLEEN; SPLEEN CELL; STEM CELL TRANSPLANTATION; STROMA CELL; SURVIVAL; UMBILICAL CORD BLOOD;

EID: 78650402526     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.3109/14653249.2010.501786     Document Type: Article

References (48)

1. Beatty PG, Hansen JA, Longton GM, Thomas ED, Sanders JE, Martin PJ, et al. Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies. Transplantation. 1991;51:443-7.
2. Martin PJ, Hansen JA, Storb R, Thomas ED. Human marrow transplantation: an immunological perspective. Adv Immunol. 1987;40:379-438.
3. Ikehara S. A new concept of stem cell disorders and their new therapy. J Hematother Stem Cell Res. 2003;12:643-53.
4. Sun Y, Tawara I, Toubai T, Reddy P. Pathophysiology of acute graft-versus-host disease: recent advances. Transl Res. 2007; 150:197-214.
5. Nash RA, Antin JH, Karanes C, Fay JW, Avalos BR, Yeager AM, et al. Phase 3 study comparing methotrexate and tacro limus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood. 2000;96:2062-8.
6. Ratanatharathorn V, Nash RA, Przepiorka D, Devine SM, Klein JL, Weisdorf D, et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood. 1998;92:2303-14.
7. Zeiser R, Marks R, Bertz H, Finke J. Immunopathogenesis of acute graft-versus-host disease: implications for novel preventive and therapeutic strategies. Ann Hematol. 2004;83: 551-65.
8. Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecifi c mitogenic stimuli. Blood. 2002;99:3838-43.
9. Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation. 2003;75:389-97.
10. Potian JA, Aviv H, Ponzio NM, Harrison JS, Rameshwar P. Veto-like activity of mesenchymal stem cells: functional discrimination between cellular responses to alloantigens and recall antigens. J Immunol. 2003;171:3426-34.
11. Krampera M, Cosmi L, Angeli R, Pasini A, Liotta F, Andreini A, et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells. 2006;24:386-98.
12. Le Blanc K. Immunomodulatory effects of fetal and adult mesenchymal stem cells. Cytotherapy. 2003;5:485-9.
13. Lazarus HM, Koc ON, Devine SM, Curtin P, Maziarz RT, Holland HK, et al. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant. 2005;11:389-98.
14. Min CK, Kim BG, Park G, Cho B, Oh IH. IL-10-transduced bone marrow mesenchymal stem cells can attenuate the severity of acute graft-versus-host disease after experimental allogeneic stem cell transplantation. Bone Marrow Transplant. 2007;39:637-45.
15. Itakura S, Asari S, Rawson J, Ito T, Todorov I, Liu CP, et al. Mesenchymal stem cells facilitate the induction of mixed hematopoietic chimerism and islet allograft tolerance without GVHD in the rat. Am J Transplant. 2007;7:336-46.
16. Ringden O, Uzunel M, Rasmusson I, Remberger M, Sundberg B, Lonnies H, et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation. 2006;81:1390-7.
17. Tisato V, Naresh K, Girdlestone J, Navarrete C, Dazzi F. Mesenchymal stem cells of cord blood origin are effective at preventing but not treating graft-versus-host disease. Leukemia. 2007;21:1992-9.
18. Gao L, Chen X, Zhang X, Liu Y, Kong P, Peng X, et al. Human umbilical cord blood-derived stromal cell, a new resource of feeder layer to expand human umbilical cord blood CD34- cells in vitro. Blood Cells Mol Dis. 2006;36:322-8.
19. Hao L, Zhang C, Chen XH, Zou ZM, Zhang X, Kong PY, et al. Human umbilical cord blood-derived stromal cells suppress xenogeneic immune cell response in vitro. Croat Med J. 2009;50:351-60.
20. Cooke KR, Kobzik L, Martin TR, Brewer J, Delmonte J Jr, Crawford JM, et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation. I. The roles of minor H antigens and endotoxin. Blood. 1996;88:3230-9.
21. Ferrara J, Guillen FJ, Sleckman B, Burakoff SJ, Murphy GF. Cutaneous acute graft-versus-host disease to minor histocompatibility antigens in a murine model: histologic analysis and correlation to clinical disease. J Invest Dermatol. 1986; 86:371-5.
22. Grass JA, Wafa T, Reames A, Wages D, Corash L, Ferrara JL, et al. Prevention of transfusion-associated graft-versus-host disease by photochemical treatment. Blood. 1999;93:3140-7.
23. Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JL. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and infl ammatory cytokines. Blood. 1997;90:3204-13.
24. Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M, et al. Treatment of severe acute graftversus- host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004;363:1439-41.
25. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008;371:1579-86.
26. Wilson J, Cullup H, Lourie R, Sheng Y, Palkova A, Radford KJ, et al. Antibody to the dendritic cell surface activation antigen CD83 prevents acute graft-versus-host disease. J Exp Med. 2009;206:387-98.
27. Jiang XX, Zhang Y, Liu B, Zhang SX, Wu Y, Yu XD, et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood. 2005;105:4120-6.
28. Nauta AJ, Kruisselbrink AB, Lurvink E, Willemze R, Fibbe WE. Mesenchymal stem cells inhibit generation and function of both CD34-derived and monocyte-derived dendritic cells. J Immunol. 2006;177:2080-7.
29. Zhang W, Ge W, Li C, You S, Liao L, Han Q, et al. Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. Stem Cells Dev. 2004;13:263-71.
30. Itoh M, Takahashi T, Sakaguchi N, Kuniyasu Y, Shimizu J, Otsuka F, et al. Thymus and autoimmunity: production of CD25- CD4- naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J Immunol. 1999;162:5317-26.
31. Stephens LA, Mason D. CD25 is a marker for CD4- thymocytes that prevent autoimmune diabetes in rats, but peripheral T cells with this function are found in both CD25- and CD25-subpopulations. J Immunol. 2000;165:3105-10.
32. Stephens LA, Mottet C, Mason D, Powrie F. Human CD4(-)CD25(-) thymocytes and peripheral T cells have immune suppressive activity in vitro . Eur J Immunol. 2001; 31:1247-54.
33. Shevach EM, McHugh RS, Piccirillo CA, Thornton AM. Control of T-cell activation by CD4- CD25- suppressor T cells. Immunol Rev. 2001;182:58-67.
34. Thornton AM, Shevach EM. CD4- CD25- immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med. 1998;188: 287-96.
35. Piccirillo CA, Shevach EM. Cutting edge: control of CD8- T cell activation by CD4- CD25- immunoregulatory cells. J Immunol. 2001;167:1137-40.
36. Annacker O, Burlen-Defranoux O, Pimenta-Araujo R, Cumano A, Bandeira A. Regulatory CD4 T cells control the size of the peripheral activated/memory CD4 T cell compartment. J Immunol. 2000;164:3573-80.
37. Hess AD, Fischer AC, Horwitz L, Bright EC, Laulis MK. Characterization of peripheral autoregulatory mechanisms that prevent development of cyclosporin-induced syngeneic graft-versus-host disease. J Immunol. 1994;153:400-11.
38. Taylor PA, Noelle RJ, Blazar BR. CD4(-) CD25(-) immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade. J Exp Med. 2001; 193:1311-8.
39. Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4(-) CD25(-) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med. 2002;196:389-99.
40. Taylor PA, Lees CJ, Blazar BR. The infusion of ex vivo activated and expanded CD4(-) CD25(-) immune regulatory cells inhibits graft-versus-host disease lethality. Blood. 2002; 99:3493-9.
41. Maccario R, Podesta M, Moretta A, Cometa A, Comoli P, Montagna D, et al. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specifi c immune response favors the differentiation of CD4- T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica. 2005;90:516-25.
42. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005; 105:1815-22.
43. Tian Y, Deng YB, Huang YJ, Wang Y. Bone marrow-derived mesenchymal stem cells decrease acute graft-versus-host disease after allogeneic hematopoietic stem cells transplantation. Immunol Invest. 2008;37:29-42.
44. von Boehmer H. Mechanisms of suppression by suppressor T cells. Nat Immunol. 2005;6:338-44.
45. Picca CC, Caton AJ. The role of self-peptides in the development of CD4- CD25- regulatory T cells. Curr Opin Immunol. 2005;17:131-6.
46. Sakaguchi S. Naturally arising Foxp3-expressing CD25- CD4- regulatory T cells in immunological tolerance to self and non-self. Nat Immunol. 2005;6:345-52.
47. Kovacsovics-Bankowski M, Streeter PR, Mauch KA, Frey MR, Raber A, vant Hof W, et al. Clinical scale expanded adult pluripotent stem cells prevent graft-versus-host disease. Cell Immunol. 2009;255:55-60.
48. Polchert D, Sobinsky J, Douglas G, Kidd M, Moadsiri A, Reina E, et al. IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol. 2008;38:1745-55.